AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. - Test2 - elhamkhani - TriplyDB

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

http://www.wikidata.org/entity/Q37564783

about

Targeting the Pim kinases in multiple myeloma Targeting Pim kinases for cancer treatment: opportunities and challenges Pim-1 kinase as cancer drug target: An update Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Control of Pim2 kinase stability and expression in transformed human haematopoietic cells Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.Pim kinases in hematological malignancies: where are we now and where are we going?Targeted therapy of acute myeloid leukemia.PIM kinase (and Akt) biology and signaling in tumors.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3.Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.PIM1: a promising target in patients with triple-negative breast cancer.

P2860

Q26799499-2B4BAB40-52EB-4BE4-B6ED-154077DB6957 Q28255361-8DF99212-57C7-43F9-AE9C-10A856944490 Q28273475-5A888889-4CAD-4AC3-B91D-AC702F3F89A2 Q28543966-82B68D8F-86D4-4252-A9F7-835BDDB95588 Q33728277-3621128F-538B-45D3-94DD-D9C70C538787 Q34489388-106EDF3C-28B4-4DE5-AC4E-841AB9F35B05 Q35078578-52F723CC-5B2A-45A4-8DD9-216DCB4C25A1 Q35573363-B14A0C0A-E01B-47B3-B1AC-4F2AAF373E49 Q35852684-B9CFAE5A-8B61-40CB-B4FF-FBDDA78B0B07 Q36276942-4EE02569-452B-4C9E-956E-0785FF484DAF Q36353641-1019316D-6408-4A8A-B443-1F6E51B9CCCE Q36413237-630F1703-D2EF-4020-9D4B-DCE5039D3228 Q36545566-7ED828AE-2E5D-4DAD-9926-81DF90C597BF Q36746585-343F266C-FAFC-4E9E-9BFD-05DDA5A88D0B Q36920449-5E731AA8-E931-42F7-ACD4-3BD52C965C9D Q37233255-E48E6DF1-A5C4-40EE-A1D1-DBD911E051BB Q37362875-CE0DB95B-BF5D-45B5-8A3A-67C372FD4D8F Q37437166-95B0F55C-0238-46E5-8561-7DF966C7A0C6 Q37628915-E68E6198-FFAF-4A13-B431-44EBDC3A22AC Q37638749-B126B336-016D-456A-BA09-501D460C9C37 Q38261268-04C8D870-7B48-4D86-B6ED-007F9B27D026 Q38262117-3CCE83E7-7D3C-43C2-8C58-3CC5EF7BCAE4 Q38285805-D8AC3B5C-431F-4C35-9B79-71A09A75A091 Q38333251-A823EF0F-241E-45B2-BBA1-E8AA8C6D2C08 Q38370023-899CCA7F-56D5-42DE-8146-4AEBBC2FD34D Q38401664-11632CDE-494F-4488-BD1A-E87FD5A70D5D Q38417153-CA2BB43E-9452-4D7D-AE4C-6F68DCE5D129 Q38681971-E9B9D0A4-62DC-47CC-9348-26B16BFD0B86 Q38720833-B7B1338C-C7A4-4CA4-B1C8-D4043FDB3047 Q38728157-4A9AC339-A798-49E0-97D4-D364D3BD315F Q38735131-376C87E4-A512-4512-9DF4-3619102CD211 Q38769889-20D0A75F-BB78-4208-A9E9-27407892D373 Q38770271-748C4206-0CA5-44E4-9F48-67142073138B Q38798340-6BE062D8-969D-4F76-A03B-2A2924829A63 Q38803880-9FDBDC1A-78AD-40CC-8FB1-ED3A65C04FBB Q38813901-8B8F69AF-6B0C-477B-A11D-390EBFDC7499 Q38934636-2E55F3D8-BA5F-4882-863E-73EB6BFD0DB1 Q38979939-320A74A7-6BDF-4192-8C29-3F5880182845 Q39253133-27E14361-95D3-4A30-A3F6-C7422660A2C4 Q39443294-AB37309F-9B1E-4FDF-B2F5-C1C8A426FDF3

P2860

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

http://www.wikidata.org/entity/Q37564783

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@en

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@nl

type

label

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@en

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@nl

prefLabel

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@en

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@nl

P1433

Q37564783-1B3A6FF7-17D6-46EF-90DB-1AEC9C57B208

P1476

Q37564783-56B143FA-3122-4EBB-A8F2-09F87351BF2A

P2093

Q37564783-08DF7573-5C4B-4AFD-8FB2-72B7281D64A8

Q37564783-159B09C6-E503-4AE6-82B3-A944ED8180A7

Q37564783-3144D9AE-B1DC-4935-8405-8DBB59A758F1

Q37564783-3D249F47-39F4-4D63-82EA-699B9F6DF5FF

Q37564783-41785641-8440-41B8-8812-BE350BB53F36

Q37564783-46257E6B-A34F-4223-B7B2-779D6C759D89

Q37564783-4FF82247-7691-4B54-B095-18B9789E8778

Q37564783-57736596-2C53-439F-81CA-250F91A15F72

Q37564783-5B286D75-FCF0-4AC5-9F64-1D8C5E3E80F0

Q37564783-63BE45A5-4F73-4BAD-A826-2AA6AFBFEFE3

P2860

Q37564783-010C30D0-AE20-403D-8EBC-0E62D0E0F217

Q37564783-06D31F41-DD5D-43F1-A2A4-9C31D3FED446

Q37564783-16EAD5EA-39F9-4672-90C4-C3D94149F447

Q37564783-1F616EB6-FF41-46F9-B3BF-6C0A7BC9A068

Q37564783-2535DE93-80D5-4620-9B76-C5EA888540A6

Q37564783-253ACE70-5F87-4EEE-94E0-AE58D3E48103

Q37564783-2EC34438-1558-4CFD-A6FF-315A3CBA7EE3

Q37564783-30255CBB-0F78-4AC0-91BF-1ADF2A4C9F87

Q37564783-30A5B2A8-C25D-4095-BFB0-D8CC35FFB2F2

Q37564783-359D5D7A-C2E0-4F0E-9399-5AF682241FDD

P304

Q37564783-55464FD7-BDF6-44FE-A6A8-91FEA54F0C35

P31

Q37564783-A3F84D8A-4158-4A45-B3C8-BA1974D61C70

P356

Q37564783-CAD27293-26B9-4341-98C4-1B81D9EE3403

P407

Q37564783-79F74F37-3B93-4B24-BE44-2BDC3DB5206E

P433

Q37564783-4F285582-6A19-41F5-840C-1A3CA2EA4C66

P478

Q37564783-C63037AB-0B9E-4ECC-9AEB-575D0B845B1C

P577

Q37564783-D8912619-994D-45BD-98FB-727AA793B2D0

P5875

Q37564783-75C9869E-A6D8-4162-A55E-A657A0480894

P698

Q37564783-284462B8-14BA-4AFB-BF29-020E69A76965

P921

Q37564783-0BB436E4-EB05-473B-8AEF-4C0866F96F06

P932

Q37564783-88CAFCC9-1B92-4B06-93A3-26934BC5C88F

P356

BLOOD-2013-04-495366

P1433

P1476

AZD1208, a potent and selectiv ...... els of acute myeloid leukemia.

@en

P2093

Allan Wu

http://www.w3.org/2001/XMLSchema#string

Daniel J Deangelo

http://www.w3.org/2001/XMLSchema#string

Dennis Huszar

http://www.w3.org/2001/XMLSchema#string

Erika K Keeton

http://www.w3.org/2001/XMLSchema#string

Francis D Gibbons

http://www.w3.org/2001/XMLSchema#string

Huawei Chen

http://www.w3.org/2001/XMLSchema#string

Keith S Dillman

http://www.w3.org/2001/XMLSchema#string

Kristen McEachern

http://www.w3.org/2001/XMLSchema#string

Leonidas C Platanias

http://www.w3.org/2001/XMLSchema#string

Les A Dakin

http://www.w3.org/2001/XMLSchema#string

P2860

Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels

The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias

Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma

Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas

The serine/threonine kinase Pim-1

P304

905-913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-04-495366

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259449492

http://www.w3.org/2001/XMLSchema#string

P698

24363397

http://www.w3.org/2001/XMLSchema#string

P921

P932

3916880

http://www.w3.org/2001/XMLSchema#string